
|Videos|April 26, 2011
Phase II AMG 386 and Paclitaxel Combination Trial
Author(s)Beth Y. Karlan MD
Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































